At the Fondazione ARTOI, we understand the importance of providing quality care to oncology patients. That is why we are excited to present the results of our latest research, which was conducted in collaboration with the National Research Council (CNR). Our study focused on integrative treatments for oncology patients, and we believe our findings will be of great benefit to both healthcare providers and patients.
The event “Current trends in integrative treatments for cancer patients” will take place on April 28, 2023, at the Marconi Room of the National Research Council in Rome. The event is organized by the ARTOI Foundation in collaboration with the Translational Pharmacology Institute of the National Research Council of Rome (CNR-IFT), to discuss the latest scientific evidence on the combined use of natural substances such as Polydatin and Curcumin in the dermatological field, in GBL patients and basic research conducted.
The conference will start with an introduction by the moderators Prof. M. Bonucci and Prof. G. Ravagnan, followed by sessions on integrative treatments for cancer patients, focusing on managing oxidative stress from radiation and dermatological therapy with natural antioxidants.
The purpose of this meeting is to present research activities carried out by the CNR-IFT of Rome-Tor Vergata on industrial research orders financed by Invitalia and the Lazio Region to different Small and Medium Enterprises. The research covers both basic and clinical research using natural molecules, already protected by international patents, which also refer to the CNR spin-off company called Glures Srl.
The conference will take place in two sessions. In the first session, clinical data will be presented on dermatological products used in cancer patients undergoing radiation therapy.
In the second session, basic research conducted on human glioblastoma (GBL) cell lines and the results of integrative therapeutic protocols, promoted by the ARTOI Foundation, will be presented.
The protocols also involved the use of a combination of Curcumin and Resveratrol Gglycoside, covered by international patents, in patients with Glioblastoma.